Division of Hematology and Oncology

Cathy Eng, MD
June 21, 2024

International overview of colorectal cancer provides multidisciplinary perspective of clinical advances

The authors hope the report will provide insight on the importance of education, screening and awareness to all health care providers.

By Tom Wilemon
May 7, 2024

Study seeks to evaluate military exposures on veterans’ lung cancer risk 

A prospective cohort of veterans including those with military toxic exposures, such as burn pits, will be screened annually with low-dose chest CT to detect lung cancer and other disease early.

By Tom Wilemon
Cathy Eng, MD
April 11, 2024

Cathy Eng to participate in April 15 congressional briefing

Cathy Eng, MD, will participate in a congressional briefing on April 15 focused on “Addressing Representation in Clinical Trials.”

By Tom Wilemon
March 28, 2024

Study identifies molecule as potential target for treating AML

While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. 

By Tom Wilemon
March 8, 2024

Scalp cooling allows woman to keep hair during chemotherapy

The Food and Drug Administration first granted marketing approval for the DigniCap system for patients with breast cancer in 2015, then in 2017 the FDA expanded the authorization, making it the first cooling cap cleared for use in cancer patients with solid tumors, such as breast cancer, ovarian cancer and colorectal cancer.

By Tom Wilemon
January 22, 2024

Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

Vanderbilt research indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.

By Tom Wilemon
January 4, 2024

Potential AML therapy induces leukemic stem cell death

Vanderbilt researchers are studying a potential therapy for acute myeloid leukemia that targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.
By Tom Wilemon
December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

By Tom Wilemon
November 17, 2023

Tumor antigens key to improving cancer immunotherapy: study

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.
By Bill Snyder
October 4, 2023

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
By Tom Wilemon
September 1, 2023

Foundation funds research to block drug resistance in cancer treatment

The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has funded an ambitious initiative to overcome one of the most perplexing and frustrating mysteries of cancer treatment — how to prevent drug resistance.
By Tom Wilemon
August 10, 2023

New leaders named to Vanderbilt-Ingram research programs

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs.
By Tom Wilemon
August 8, 2023

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.
By Tom Wilemon
1 2 3 4 … 15